Financial Ratios Entheon Biomedical Corp.
Equities
ENBI
CA29383X2023
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1700 CAD | 0.00% | +6.25% | +70.00% |
Fiscal Period: November | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Profitability | |||||
Return on Assets | - | -44.49 | -78.77 | -41.88 | -33.54 |
Return on Total Capital | - | -54.11 | -88.96 | -46.57 | -42.19 |
Return On Equity % | - | -231.39 | -138.91 | -42.66 | -64.49 |
Return on Common Equity | - | -231.39 | -138.91 | -42.66 | -64.49 |
Margin Analysis | |||||
Gross Profit Margin % | - | - | 42.13 | 100 | 100 |
SG&A Margin | - | - | 21.14K | 1.32K | 224.96 |
EBITDA Margin % | - | - | -41.86K | -1.87K | - |
EBITA Margin % | - | - | -42.02K | -1.9K | -125.43 |
EBIT Margin % | - | - | -42.02K | -1.9K | -125.43 |
Income From Continuing Operations Margin % | - | - | -41.01K | -1.09K | -119.85 |
Net Income Margin % | - | - | -41.01K | -4.49K | -119.85 |
Net Avail. For Common Margin % | - | - | -41.01K | -1.09K | -119.85 |
Normalized Net Income Margin | - | - | -26.23K | -1.1K | -76 |
Levered Free Cash Flow Margin | - | - | -9.88K | -897.27 | -100.58 |
Unlevered Free Cash Flow Margin | - | - | -9.88K | -897.27 | -100.58 |
Asset Turnover | |||||
Asset Turnover | - | - | 0 | 0.04 | 0.43 |
Fixed Assets Turnover | - | - | 0.25 | - | - |
Short Term Liquidity | |||||
Current Ratio | 1.45 | 6.05 | 3.46 | 4.81 | 4.64 |
Quick Ratio | 1.22 | 4 | 2.24 | 4.67 | 4.11 |
Operating Cash Flow to Current Liabilities | -5 | -3.9 | -6.05 | -12.79 | -4.22 |
Long Term Solvency | |||||
Total Debt/Equity | 7.18 | - | - | - | - |
Total Debt / Total Capital | 6.7 | - | - | - | - |
Total Liabilities / Total Assets | 69.19 | 16.28 | 9.3 | 20.1 | 21.27 |
Net Debt / EBITDA | - | 1.73 | 0.23 | 0.19 | - |
Net Debt / (EBITDA - Capex) | - | 1.72 | 0.22 | 0.19 | - |
Growth Over Prior Year | |||||
Total Revenues, 1 Yr. Growth % | - | - | - | - | 31.97 |
Gross Profit, 1 Yr. Growth % | - | - | - | - | 31.97 |
EBITDA, 1 Yr. Growth % | - | - | 453.75 | -56.68 | - |
EBITA, 1 Yr. Growth % | - | 149.14 | 455 | -56.17 | -91.28 |
EBIT, 1 Yr. Growth % | - | 149.14 | 455 | -56.17 | -91.28 |
Earnings From Cont. Operations, 1 Yr. Growth % | - | 556.63 | 102.82 | -74.23 | -85.45 |
Net Income, 1 Yr. Growth % | - | 556.63 | 102.82 | -4.12 | -96.48 |
Normalized Net Income, 1 Yr. Growth % | - | 146.04 | 107.71 | -59.43 | -90.86 |
Diluted EPS Before Extra, 1 Yr. Growth % | - | 2 | 2.52 | -76.32 | -85.45 |
Net Property, Plant and Equip., 1 Yr. Growth % | - | - | 2.5K | - | - |
Total Assets, 1 Yr. Growth % | - | 3.17K | 123.06 | -92.29 | -47.86 |
Tangible Book Value, 1 Yr. Growth % | - | 8.78K | -15.94 | -80.48 | -48.62 |
Common Equity, 1 Yr. Growth % | - | 8.78K | 141.66 | -93.21 | -48.62 |
Cash From Operations, 1 Yr. Growth % | - | 499.55 | 97.89 | -62.89 | -81.59 |
Capital Expenditures, 1 Yr. Growth % | - | - | 984.58 | - | - |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | 10.48 | -13.62 | -85.21 |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | 10.48 | -13.62 | -85.21 |
Compound Annual Growth Rate Over Two Years | |||||
EBITDA, 2 Yr. CAGR % | - | - | - | 47.07 | - |
EBITA, 2 Yr. CAGR % | - | - | 271.85 | 48.13 | -80.45 |
EBIT, 2 Yr. CAGR % | - | - | 271.85 | 48.13 | -80.45 |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | - | 264.94 | -31.41 | -80.63 |
Net Income, 2 Yr. CAGR % | - | - | 264.94 | 39.45 | -81.63 |
Normalized Net Income, 2 Yr. CAGR % | - | - | 269.15 | -12.8 | -80.74 |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | 2.26 | -53.26 | -81.44 |
Total Assets, 2 Yr. CAGR % | - | - | 753.82 | -58.53 | -79.95 |
Tangible Book Value, 2 Yr. CAGR % | - | - | 763.98 | -59.49 | -68.33 |
Common Equity, 2 Yr. CAGR % | - | - | 1.36K | -59.49 | -81.32 |
Cash From Operations, 2 Yr. CAGR % | - | - | 244.45 | -16.51 | -74.01 |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | - | -6.3 | -64.25 |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | - | -6.3 | -64.25 |
Compound Annual Growth Rate Over Three Years | |||||
EBITA, 3 Yr. CAGR % | - | - | - | 76.16 | -42.37 |
EBIT, 3 Yr. CAGR % | - | - | - | 76.16 | -42.37 |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | - | 45.64 | -59.09 |
Net Income, 3 Yr. CAGR % | - | - | - | 133.74 | -59.09 |
Normalized Net Income, 3 Yr. CAGR % | - | - | - | 70.87 | -58.88 |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | -39.37 | -68.32 |
Total Assets, 3 Yr. CAGR % | - | - | - | 77.79 | -55.24 |
Tangible Book Value, 3 Yr. CAGR % | - | - | - | 144.25 | -56.15 |
Common Equity, 3 Yr. CAGR % | - | - | - | 144.25 | -56.15 |
Cash From Operations, 3 Yr. CAGR % | - | - | - | 61.07 | -49.76 |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | -49.36 |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | -49.36 |
- Stock Market
- Equities
- ENBI Stock
- Financials Entheon Biomedical Corp.
- Financial Ratios